|
Patent landscape, scope, and claims: |
Executive summary
US Patent 7,033,605 claims in one family a set of intraocular, bioerodible depot constructs based on PLGA (polylactic acid-polyglycolic acid), loaded with steroidal immunosuppressants (including dexamethasone and cyclosporine A as exemplars) and designed for release of at least ~3 weeks from a single pellet or single extruded filament, plus related method claims for (i) preventing ocular transplant rejection and (ii) treating/preventing ocular neovascularization. The patent’s enforceable scope is primarily concentrated on (a) intraocular placement, (b) PLGA and specific “no added release modifier” limitations, (c) particle-in-polymer drug dispersion, (d) single-dose depot formats (pellet or extruded filament), and (e) functional release duration/amount ranges. The breadth is materially reduced by its combination of structural and functional constraints and by the presence/absence of “no release modifier” and the ≥3 week release requirement.
US Drug Patent 7,033,605: core claim scope, coverage map, and landscape
What patents protect US 7,033,605 transplant rejection and intraocular PLGA steroid depots?
Directly claimed subject matter
US 7,033,605 contains a claim set that can be read as three overlapping coverage groups:
1) Ocular transplant rejection prevention (method + device)
- Method claim 1: prevents transplant rejection in an eye by:
- performing an ocular transplant procedure, and
- implanting a bioerodible drug delivery system comprising a steroidal immunosuppressive agent and bioerodible polymer effective when released to prevent rejection.
- Device-dependent claims 2–20: intraocular bioerodible systems with:
- PLGA copolymer specifically recited in claim 2,
- including no added release modifier (explicit),
- release over at least about 3 weeks,
- single pellet or single extruded filament format,
- drug present as particles (claim 3),
- immunosuppressive agent (claims 4–7, with a long non-exhaustive style list; claim 6 is dexamethasone; claim 7 is cyclosporine A),
- drug weight % ranges (claims 10–11 for the drug generally; claims 17–18 for dexamethasone),
- polymer as a polyester (claim 12) and specifically PLGA (claim 20),
- implantation sites specified as anterior chamber (claim 8) and vitreous cavity (claim 9).
2) Dexamethasone-specific transplant rejection depot (stricter sub-set)
- Device claim 13: intraocular bioerodible system with:
- dexamethasone + bioerodible copolymer,
- including no release modifier,
- dexamethasone present as particles in copolymer,
- single pellet or single extruded filament.
- Dependent claims 14–19: include release ≥3 weeks, anterior/vitreous implantation, dexamethasone wt% windows, and PLGA/polyester recitations.
3) Neovascularization prevention/treatment (steroid + PLGA, depot placement implied)
- Device claims 21–30:
- intraocular bioerodible system comprising a steroid effective for preventing/reducing neovascularization plus PLGA,
- formation of implant for placement in an eye prone to neovascularization,
- no release modifier recited in claim 23,
- steroid wt% ranges (claims 24, 27),
- steroid as particles homogenously distributed (claim 28),
- vitreous placement (claim 29),
- steroid specified as anti-inflammatory steroid (claim 30),
- dexamethasone is an exemplar (claim 22).
- Method claim 31: treating neovascularization by implanting an intraocular bioerodible drug delivery system comprising immunosuppressive agent + PLGA.
- Device claim 32: general particle-in-PLGA depot for release ≥3 weeks and single pellet or single extruded filament.
What are the main independent claim limitations in US 7,033,605, and how do they narrow infringement risk?
Independent-ish anchors (from your provided claim text)
Even if some claims are “dependent,” they repeatedly reintroduce the same binding constraints. The enforceability hinge is the combination of limitations:
-
Intraocular implantation
- Explicit in device claims (anterior chamber and vitreous cavity recitations exist as dependents).
- Functional “in the eye” language appears across claims.
-
Bioerodible drug delivery system using PLGA (or PLGA-copolymer)
- Claim 2: PLGA copolymer recited.
- Claim 20: PLGA copolymer recited again.
- Claims 21+ repeatedly use PLGA in neovascularization coverage.
-
No added release modifier
- Claim 2: “including no added release modifier”
- Claim 13/21+ variations: “including no release modifier”
- This is a key design-around lever: adding a release modifier outside the “no added release modifier” boundary can potentially move an accused product outside the literal claim language.
-
Particle form drug in polymer
- Claim 3: “drug present as particles in the bioerodible polymer”
- Claim 13: dexamethasone present as particles in copolymer
- Claim 28: steroid particles homogenously distributed
- A non-particulate dispersion format could be an infringement-avoidance design point, depending on the claim construction of “particles.”
-
Release duration at least ~3 weeks
- Claims 2 and 13 and others require releasing over “at least about 3 weeks.”
- Claim 32 similarly requires “at least about 3 weeks.”
- Shorter release kinetics can reduce or eliminate meeting this functional requirement.
-
Single pellet or single extruded filament
- Claim 2: “single pellet or a single extruded filament”
- Claim 13: same format limitation
- Claim 32: same format limitation
- Multi-pellet arrays, multi-filament devices, or different depot architectures are potential non-infringing alternatives if they avoid this “single” characterization.
-
Specific drug exemplars and weight % windows
- Drug list is extensive (claim 5), but direct examples include:
- dexamethasone (claim 6)
- cyclosporine A (claim 7)
- many other immunosuppressants/antimetabolites/antiproliferatives are recited in the list (claim 5)
- Weight % ranges:
- general drug: 10–90% (claim 10), 50–80% (claim 11)
- dexamethasone: 10–90% (claim 17), 50–80% (claim 18)
- steroid: 10–90% (claim 24), 50–80% (claim 27)
- These ranges are additional gating limitations; products with load outside windows can avoid those dependent claims but may still risk coverage under broader independent/devices if those dependent constraints are not required.
How broad is US 7,033,605 for transplant rejection drugs: dexamethasone vs cyclosporine A vs “steroidal immunosuppressive agents”?
Dexamethasone (high-confidence coverage within your claim set)
- Claim 6 and claim 13–20 anchor dexamethasone in PLGA particle-in-polymer depots with:
- no release modifier
- single pellet/filament
- ≥3 week release
- anterior/vitreous placement as dependents
- dexamethasone wt% ranges in claims 17–18
This makes dexamethasone-loaded PLGA depots for post-ocular transplant rejection prevention the most straightforward “match” to the claim language.
Cyclosporine A (claimed but scope is more dependent on meeting other depot constraints)
- Claim 7 includes cyclosporine A as an immunosuppressive agent.
- But the device claim 2 has additional constraints (PLGA, no added release modifier, ≥3 week release, pellet/filament).
- If an accused product uses cyclosporine A but differs on particle form, depot “single” format, or release duration, risk changes.
“Steroidal immunosuppressive agent” vs non-steroidal immunosuppressants
- Your claim 1 uses “steroidal immunosuppressive agent.”
- Your device claims 4–7 and the long list in claim 5 include agents that may not all be “steroidal” in the classical chemical sense. In litigation, claim construction of “steroidal” and how it applies to the enumerated list becomes important for scope.
- On the face of your provided claims, dexamethasone is clearly within “steroidal,” while cyclosporine A is typically non-steroidal. That mismatch can narrow or complicate coverage for agents outside the steroid class, depending on how the court interprets the claim’s category language relative to the enumerated list.
What formulations are protected: PLGA copolymer particle-in-polymer, no release modifier, pellet or filament?
Protected formulation “core”
Your claim text repeats the same formulation skeleton:
- Polymer: PLGA copolymer (explicit in claim 2; explicit/linked in claims 19–20).
- Drug presentation: particles distributed in polymer (explicit in claims 3, 13, 28; “particles” is also in claim 32).
- Release control: “no added release modifier.”
- This is not just a process limitation, it is a materials composition limitation as written.
- Depot geometry: single pellet or single extruded filament.
- Release profile: release over ≥ about 3 weeks
- “at least about 3 weeks” appears consistently.
Protected implantation contexts
- Transplant rejection prevention: anterior chamber (claim 8) and vitreous cavity (claim 9) dependents under the PLGA/delivery-system claims.
- Neovascularization: vitreous placement (claim 29) and general intraocular implant for an eye prone to neovascularization in claim 21.
When does US 7,033,605 lose exclusivity: expiration timeline and exclusivity drivers?
No usable filing or patent grant dates
Your prompt provides the claim text but not the patent’s:
- filing date,
- non-provisional filing date,
- priority date,
- patent grant date,
- terminal disclaimer status,
- maintenance fee schedule,
- any patent term adjustment (PTA) or patent term extension (PTE),
- patent subject matter (small molecule vs biologic, which affects regulatory extension routes).
Without those dates and procedural history, a correct and complete exclusivity/expiration timeline cannot be produced from the provided information.
Which generic entry risks exist for the US 7,033,605 claim scope?
Entry risk profile by design-around axis
Based strictly on your claim limitations, the most direct generic/biosimilar entry risks cluster around accused products that match the “core” skeleton:
- Same polymer system: PLGA copolymer.
- Same depot architecture: single pellet or single extruded filament.
- Same drug dispersion: drug particles in polymer.
- Same composition rule: no added release modifier.
- Same release duration: ≥ about 3 weeks.
- Same indication-to-delivery pairing:
- For transplant rejection: ocular transplant context and prevention/reduction of transplant rejection when released.
- For neovascularization: steroid effective to prevent/reduce neovascularization.
Likely generic risk zones
- Dexamethasone + PLGA particle-in-polymer pellet/filament, with release ≥3 weeks and no release modifier, implanted post-transplant (anterior chamber or vitreous).
- Steroid + PLGA particle-in-polymer implant for neovascularization, with the same depot constraints and vitreous placement if required by dependent claims.
Likely mitigations
- Changing depot format away from “single pellet or single extruded filament” (for example, multiple pellets or non-pellet continuous systems) could reduce literal coverage.
- Adding a release modifier can attempt to avoid the “no release modifier” limitation.
- Reducing release duration below “at least about 3 weeks” can avoid meeting the functional claim element (and can also weaken §271(f)-type theories depending on construction).
- Drug substitutions:
- If the asserted claims require “steroidal immunosuppressive agent,” choosing non-steroidal immunosuppressants can become a coverage question.
- If the asserted claims instead rely on the enumerated list, substitutes outside the list can fall outside at least some claim coverage.
How does US 7,033,605 compare with typical PLGA ocular depot patents and what does that imply for claim strength?
Claim strength drivers in your text
- Specific combination of:
- intraocular use,
- PLGA copolymer,
- no release modifier,
- particles in polymer,
- single pellet/filament,
- release duration floor (≥3 weeks),
- and indication-specific endpoints (transplant rejection and neovascularization).
This combination can be harder to design around than a broad “any PLGA ocular steroid” claim, but it can also narrow enforceability if accused products deviate on any one element.
Claim vulnerability drivers in your text
- The “no added release modifier” and “single pellet or single extruded filament” constraints can be attacked if accused products use different release-control strategies or depot forms.
- “at least about 3 weeks” is a functional threshold. If data show shorter release or a different effective release window, coverage can be contested.
- The “steroidal immunosuppressive agent” category can be a focal point if asserted against drugs that are in the enumerated list but not steroidal.
What patent litigation affects US 7,033,605, and are there known settlements?
No litigation dataset provided
Your prompt includes only claim text and does not provide:
- case captions,
- parties,
- Paragraph IV filings,
- district court/jurisdiction,
- settlement dates,
- ITC actions,
- consent decrees.
A correct litigation and settlement analysis cannot be produced from the information provided.
What is the Orange Book status of products covered by US 7,033,605?
No product/NDC mapping provided
US Orange Book status requires linking the patent to:
- specific FDA-approved NDA/ANDA products,
- active ingredient(s),
- dosage form and route,
- Orange Book patent list entries.
Your prompt does not include any product identifiers or Orange Book listing data for US 7,033,605, so an Orange Book status answer cannot be generated from the provided information.
Commercial exposure: which ocular transplant rejection/neovascularization products face patent estate risk under US 7,033,605?
No market or product mapping provided
Commercial exposure depends on identifying which marketed intraocular PLGA steroid/particle depots are in-use for:
- ocular transplant rejection prophylaxis,
- neovascularization treatment/prevention.
Your prompt provides no product names, brand/NDC lists, or commercial adoption information. A quantified exposure map cannot be produced from the provided information.
Geographic coverage: is US 7,033,605 relevant outside the US?
No family data provided
International relevance requires:
- corresponding PCT/EP/WO publications,
- national phase entries,
- grant status per jurisdiction,
- claim translations and claim amendments.
Your prompt provides only the US patent number and claim text, with no family/jurisdiction mapping. A geographic claim coverage analysis cannot be completed.
Key Takeaways
- US 7,033,605 is centered on intraocular bioerodible depot systems using PLGA copolymer with particle-loaded drug, no added release modifier, single pellet or single extruded filament form, and ≥ about 3 weeks release.
- The patent provides explicit coverage for:
- ocular transplant rejection prevention (method claim 1, device claims 2–20),
- dexamethasone-specific transplant rejection depots (claims 13–20),
- steroid-based neovascularization reduction (claims 21–30),
- and a broad particle-in-PLGA ≥3 week pellet/filament device concept (claim 32).
- The most important design-around and infringement screening variables are:
- whether a product uses PLGA,
- whether it uses no release modifier,
- whether the depot is single pellet/filament,
- whether the drug is in particle form within the polymer,
- and whether release is ≥3 weeks.
- Claim strength is high where an accused product matches the combination of those constraints and the intended ocular indication endpoints; it weakens if a challenger can change even one gating limitation.
FAQs
- Does US 7,033,605 require steroidal immunosuppressants specifically, or does the listed immunosuppressant set control breadth?
- What elements most strongly differentiate infringement between claim 2 vs claim 13 (dexamethasone-specific) in practice?
- How does the “no added release modifier” limitation affect common PLGA ocular depot formulation strategies?
- If an accused device releases over 2 weeks instead of ≥3 weeks, which dependent claim elements become most vulnerable?
- For neovascularization implants, is vitreous placement a mandatory limitation for all asserted claims or only for certain dependents?
References (APA)
- United States Patent 7,033,605. “Method for preventing transplant rejection in an eye and bioerodible drug delivery systems.” Claims as provided in the prompt.
More… ↓
⤷ Start Trial
|
